The FDA said anti-clotting drug Plavix will include a warning about its diminished effect on patients who have a problem breaking it down. Between 2% and 14% of the population poorly metabolize the drug, the agency said. Bristol-Myers Squibb, one of the sellers of the drug, said patients should continue taking the medicine unless otherwise advised by a health care professional.

Full Story:

Related Summaries